Given the well-documented pharmacological limitations of SB290157, our results do not confirm a definitive regulatory role for C3aR, but identify C3aR as a candidate mediator of mesangial matrix deposition in DKD, providing preliminary evidence that targeting C3aR may represent a potential therapeutic strategy for diabetic kidney disease. Here, C3AR1 is linked to diabetic kidney disease.